Clinical Trial Update: Study of Bacillus Calmette-Guerin (BCG) Combined With PANVAC Versus BCG Alone in Adults With High Grade Non-Muscle Invasive Bladder Cancer Who Failed At Least 1 Course of BCG [Phase 2]

View source ↗

Summary

Phase 2 study comparing BCG alone vs BCG plus PANVAC in adults with high-grade non-muscle invasive bladder cancer after BCG failure; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-muscle Invasive Bladder Cancer

Drugs mentioned

• Bacillus Calmette-Guérin (BCG) (Bacillus Calmette-Guérin)
• PANVAC (PANVAC-V (CEA/MUC1 TRICOM))

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Bladder Cancer | Phase 2 | Status: COMPLETED | Results posted: 2020-01-22